This invention relates to a transdermal delivery device for the controlled transdermal delivery of nitroglycerin at in vivo transdermal fluxes of at least 40 ??g/cm2 /hr and preferably substantially higher, for use in the treatment of such conditions as angina pectoris and congestive heart failure.